- Lead Boston Discovery Center (BDC), partnership with the Baran and Cravatt labs at Scripps, and corporate- and business development- Helped close €1.1B licensing deal w Boehringer Ingelheim for Bridge's PI autotaxin inhibitor for IPF, one of the largest biotech deals in Korea- Bridge is a clinical stage biotech company developing first-in-class or best-in-class peptide and small molecule drugs for auto-immune disease and fibrosis; went public on KOSDAQ in Dec 2019

- Serve on venture Selection Committee. BaseLaunch is an accelerator located in one of the most active life sciences hubs in Europe. Since its founding in 2018, BL has supported seed-stage ventures that have since raised over $550M. Other selection committee members are represented by global big pharma, leading biotech and VCs.

Lipella is a clinical-stage biotech company developing drugs as supportive care for cancer survivors and for orphan indications. Its first product candidate LP-10, which utilizes Lipella’s proprietary drug delivery platform, is currently in P2 clinical study to treat bleeding and pain in hemorrhagic cystitis of the bladder.

- FMI operates on first-in-class platform/strategy to source, evaluate and invest in early-stage biotech companies

- Private partnership and investment platform for like-minded partners

- Responsible for all aspects of launching, investment, portfolio support and the Fund operations- KSLSF (www.kslsfund.com) is a cross-Pacific venture capital fund which invests in and supports emerging life sciences companies in S. Korea and the US; KSLSF was founded as partnership between Oxford Bioscience Partners of the US (later, spun off KSLSF as an independent fund from Oxford) and Hanwha (a top 10 conglomerate in Korea); KSLSF was the largest dedicated biotech VC fund in Korea at the time of founding; liquidated successfully after almost 13 years of run

- Advise BD, corporate development and R&D portfolio strategies; CKD is a top-5 pharma company in Korea

- Served as the first independent board member- CytoReason is an AI-enabled biotechnology company focused on data analytics and target discovery with expertise in immunology; CytoReason has signed partnership with multiple big pharmas.

- PharmAbcine is a clinical stage oncology company, went public KOSDAQ:208340

- Oxford Bioscience Partners is a venture capital firm that provides equity financing and management assistance to entrepreneurial-driven companies within the life sciences and healthcare sectors; the firm has invested in over 140 life science companies worldwide and has an AUM $1B

Various consulting and advisory including for Leerink, a Puretech portfolio, etc.

- Led corporate development, strategy and operations of NIBR and Global BioMarker Development Group (served as Global Head & Associate Director)- The Novartis Institutes for BioMedical Research is the global pharmaceutical research organization of Novartis; headquartered in Cambridge, USA, and with ~5,000 scientists and physicians around the world, it is focused on discovering innovative new drugs that will change the practice of medicine

- Developed blueprint to support Emerging Business Opportunities initiative of IBM Healthcare and Life Sciences- The Extreme Blue™ program is IBM's premier program for people pursuing software development or business degrees

- Conducted PhD graduate biomedical research in developmental biology using mouse genetics and transgenic approaches; published two leading/co-leading publications- MD Anderson is a comprehensive cancer center and is ranked the top cancer hospital in the US